MUMBAI: The Ranbaxy brand may be allowed to die a slow death over the next two to three years by the company's new owner - Sun Pharma - due to the negativity surrounding its product quality. Sun Pharma announced on Monday that it will buy the country's largest company by revenue, Ranbaxy, from Japanese parent Daiichi Sankyo in an all-stock deal valued at $3.2 billion, besides also acquiring Ranbaxy's debt of around $800 million, taking the overall transaction value to $4 billion. Over the last six years or so, the half a century old brand has taken a massive hit on its equity, particularly in the US market due to quality and manufacturing issues. These concerns over a period trickled down to the Indian market with the brand facing "a trust issue" with patients, doctors and hospitals. So much so that there were even safety concerns in the domestic market over some of its popular medicines.